| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
|
Bellinvia, Salvatore
|
|
2019
|
33 |
3 |
p. 241-253
|
artikel
|
| 2 |
Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
|
Bellinvia, Salvatore
|
|
|
33 |
3 |
p. 241-253
|
artikel
|
| 3 |
A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin®) in Healthy Male Subjects
|
Wu, Xiaoyun
|
|
2019
|
33 |
3 |
p. 335-342
|
artikel
|
| 4 |
A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin®) in Healthy Male Subjects
|
Wu, Xiaoyun
|
|
|
33 |
3 |
p. 335-342
|
artikel
|
| 5 |
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
|
Hutterer, Katariina M.
|
|
2019
|
33 |
3 |
p. 321-333
|
artikel
|
| 6 |
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
|
Hutterer, Katariina M.
|
|
|
33 |
3 |
p. 321-333
|
artikel
|
| 7 |
Correction to: Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
|
McCafferty, Emma H.
|
|
2019
|
33 |
3 |
p. 343
|
artikel
|
| 8 |
Correction to: Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
|
McCafferty, Emma H.
|
|
|
33 |
3 |
p. 343
|
artikel
|
| 9 |
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting
|
Moorkens, Evelien
|
|
2019
|
33 |
3 |
p. 299-306
|
artikel
|
| 10 |
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting
|
Moorkens, Evelien
|
|
|
33 |
3 |
p. 299-306
|
artikel
|
| 11 |
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting
|
Moorkens, Evelien
|
|
2019
|
33 |
3 |
p. 285-297
|
artikel
|
| 12 |
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting
|
Moorkens, Evelien
|
|
|
33 |
3 |
p. 285-297
|
artikel
|
| 13 |
Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
|
Gorovits, Boris
|
|
2019
|
33 |
3 |
p. 275-284
|
artikel
|
| 14 |
Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
|
Gorovits, Boris
|
|
|
33 |
3 |
p. 275-284
|
artikel
|
| 15 |
PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review
|
Cook, Sarah A.
|
|
2019
|
33 |
3 |
p. 255-273
|
artikel
|
| 16 |
PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review
|
Cook, Sarah A.
|
|
|
33 |
3 |
p. 255-273
|
artikel
|
| 17 |
Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar
|
Cerutti, María L.
|
|
2019
|
33 |
3 |
p. 307-319
|
artikel
|
| 18 |
Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar
|
Cerutti, María L.
|
|
|
33 |
3 |
p. 307-319
|
artikel
|
Tijdschrift beschrijving